Gut Microbiota Biomarkers in Patients with Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors
Life · 10.04.2026 · 16 (4) · 641
DOI: 10.3390/life16040641 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Life, online erschienen am 10.04.2026. Verfasst von Maria Cerreto und 7 weiteren Autor:innen. Beteiligte Einrichtung: Liver Unit-Centro Malattie dell'Apparato Digerente (CEMAD), Medicina Interna e Gastroenterologia, Fondazione Policlinico Universitario Gemelli IRCCS,…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have revolutionized the therapeutic landscape for hepatocellular carcinoma (HCC); however, a considerable proportion of patients do not achieve durable clinical benefits. This highlights the need for reliable predictive biomarkers, which are currently lacking. The accumulated evidence supports a relevant role of the gut–liver axis in modulating immunotherapy outcomes, and several studies have identified distinct microbial features associated with either responders or non-responders. Responders to immunotherapy frequently present with higher microbial diversity and enrichment of beneficial taxa, whereas the expansion of pro-inflammatory and pathogenic bacteria has been associated with primary resistance and increased treatment-related toxicity in non-responders. However, the available findings remain heterogeneous across cohorts, likely owing to differences in geography, diet, liver disease etiology, treatment regimens, and microbiome analytical methods. Machine-learning models integrating metagenomic and metabolomic data have shown encouraging results in defining microbial signatures associated with treatment outcomes, although variability among cohorts currently limits their clinical applicability and generalizability. Beyond microbial taxonomic composition, microbiota-derived metabolites—such as short-chain fatty acids, bile acids, inosine, and tryptophan catabolites—appear to play a crucial role in shaping the tumor microenvironment and host immune responses, thus representing additional candidate biomarkers, also due to the relative ease of their measurement. Finally, microbiota-targeted interventions are emerging as potential strategies to enhance immunotherapy efficacy. Overall, the gut microbiome and its metabolic activity represent promising tools, albeit still under investigation, for patient stratification and personalized management in HCC treated with ICIs. Therefore, this review aims to summarize and critically discuss the current evidence on gut microbiota-derived biomarkers of response and resistance to ICIs in HCC, with particular focus on microbial composition, microbiota-related metabolites, and emerging microbiome-based therapeutic strategies. This narrative review provides an updated overview of the role of gut microbiota as both a biomarker and a therapeutic target in patients with hepatocellular carcinoma (HCC) receiving immune checkpoint inhibitor (ICI) therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Liver Unit-Centro Malattie dell'Apparato Digerente (CEMAD), Medicina Interna e Gastroenterologia, Fondazione Policlinico Universitario Gemelli IRCCS, 00168 Rome, Italy.
- Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
ORCID-Profile: Maria Cerreto, Marta Maestri, Lucia Cerrito, Leonardo Stella, Antonio Gasbarrini, Francesca Romana Ponziani
Zitieren
APA
Cerreto, M., Maestri, M., Pallozzi, M., Cerrito, L., Stella, L., Ianiro, G., Gasbarrini, A., & Ponziani, F. R. (2026). Gut Microbiota Biomarkers in Patients with Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors. Life, 16(4), 641. https://doi.org/10.3390/life16040641
Vancouver
Cerreto M, Maestri M, Pallozzi M, Cerrito L, Stella L, Ianiro G, et al. Gut Microbiota Biomarkers in Patients with Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors. Life. 2026;16(4):641. doi:10.3390/life16040641
BibTeX
@article{Cerreto2026,
author = {Cerreto, Maria and Maestri, Marta and Pallozzi, Maria and Cerrito, Lucia and Stella, Leonardo and Ianiro, Gianluca and Gasbarrini, Antonio and Ponziani, Francesca Romana},
title = {Gut Microbiota Biomarkers in Patients with Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors},
journal = {Life},
year = {2026},
volume = {16},
number = {4},
pages = {641},
doi = {10.3390/life16040641}
}
EUVIMED